AAV gene therapy vectors in the TMJ

Sabine M. Brouxhon; Michael Kerry O'Banion; Stephanos Kyrkanides

doi:10.1002/cre2.636

AAV gene therapy vectors in the TMJ

Sabine M. Brouxhon, Michael Kerry O'Banion, Stephanos Kyrkanides

Oral Health Science

Research output: Contribution to journal › Article › peer-review

1 Scopus citations

Abstract

Objectives: The goal of this project was to evaluate the use of two adeno-associated viral vector serotypes, adeno-associated viral vectors (AAV)-2 and AAV-6, approved for and used for gene therapy in humans, for the delivery of therapeutic genes to the temporomandibular joint (TMJ) and the attendant sensory nerves. Methods: Young adult wild-type C57BL/6 mice were intra-articularly inoculated with AAV-2 and AAV-6 encoding the reporter gene gfp, the expression of which was assessed in the TMJ as well as along nerves innervating the TMJ. Results: AAV-2 and AAV-6 serotypes were characterized by varying levels of tissue tropism demonstrating different efficacy of infection for articular chondrocytes, meniscal fibroblasts, and trigeminal neurons. Specifically, AAV-2 infected both neurons and articular chondrocytes/meniscal fibroblasts, whereas AAV-6 showed selectivity primarily for neurons. Conclusions: The results of this study are clinically significant in the successful application of gene therapy vectors for TMJ disorders, as this new knowledge will allow for appropriate targeting of specific therapeutic genes to selective tissues (neurons vs. chondrocytes/fibroblasts) as needed by using specific viral vector serotypes.

Original language	English
Pages (from-to)	1561-1566
Number of pages	6
Journal	Clinical and Experimental Dental Research
Volume	8
Issue number	6
DOIs	https://doi.org/10.1002/cre2.636
State	Published - Dec 2022

Bibliographical note

Funding Information:
We would like to thank Dr. Ross H. Tallents and Ms. Jen‐nie H. Miller for their assistance in animal care, injection of the viral vectors, animal euthanasia, and tissue processing. We would also like to express our gratitude to Dr. Brandon Harvey, Chief, Molecular Mechanisms of Cellular Stress and Inflammation, and Director of the Transgenic Rat Project, who packaged the AAV vectors at the National Institute for Drug Abuse/National Institute of Health. This study was funded in part by NIH grants AR055035 and DE017765 to S. K., as well as start‐up funding provided to S. K. from the Eastman Dental Foundation through the University of Rochester Eastman Institute for Oral Health.

Publisher Copyright:
© 2022 The Authors. Clinical and Experimental Dental Research published by John Wiley & Sons Ltd.

Keywords

TMJ
gene therapy
trigeminal nerve
vectors

ASJC Scopus subject areas

Dentistry (all)

Access to Document

10.1002/cre2.636

Cite this

@article{93f030524a9245e98890feed6a474710,

title = "AAV gene therapy vectors in the TMJ",

abstract = "Objectives: The goal of this project was to evaluate the use of two adeno-associated viral vector serotypes, adeno-associated viral vectors (AAV)-2 and AAV-6, approved for and used for gene therapy in humans, for the delivery of therapeutic genes to the temporomandibular joint (TMJ) and the attendant sensory nerves. Methods: Young adult wild-type C57BL/6 mice were intra-articularly inoculated with AAV-2 and AAV-6 encoding the reporter gene gfp, the expression of which was assessed in the TMJ as well as along nerves innervating the TMJ. Results: AAV-2 and AAV-6 serotypes were characterized by varying levels of tissue tropism demonstrating different efficacy of infection for articular chondrocytes, meniscal fibroblasts, and trigeminal neurons. Specifically, AAV-2 infected both neurons and articular chondrocytes/meniscal fibroblasts, whereas AAV-6 showed selectivity primarily for neurons. Conclusions: The results of this study are clinically significant in the successful application of gene therapy vectors for TMJ disorders, as this new knowledge will allow for appropriate targeting of specific therapeutic genes to selective tissues (neurons vs. chondrocytes/fibroblasts) as needed by using specific viral vector serotypes.",

keywords = "TMJ, gene therapy, trigeminal nerve, vectors",

author = "Brouxhon, {Sabine M.} and O'Banion, {Michael Kerry} and Stephanos Kyrkanides",

note = "Funding Information: We would like to thank Dr. Ross H. Tallents and Ms. Jen‐nie H. Miller for their assistance in animal care, injection of the viral vectors, animal euthanasia, and tissue processing. We would also like to express our gratitude to Dr. Brandon Harvey, Chief, Molecular Mechanisms of Cellular Stress and Inflammation, and Director of the Transgenic Rat Project, who packaged the AAV vectors at the National Institute for Drug Abuse/National Institute of Health. This study was funded in part by NIH grants AR055035 and DE017765 to S. K., as well as start‐up funding provided to S. K. from the Eastman Dental Foundation through the University of Rochester Eastman Institute for Oral Health. Publisher Copyright: {\textcopyright} 2022 The Authors. Clinical and Experimental Dental Research published by John Wiley & Sons Ltd.",

year = "2022",

month = dec,

doi = "10.1002/cre2.636",

language = "English",

volume = "8",

pages = "1561--1566",

number = "6",

}

TY - JOUR

T1 - AAV gene therapy vectors in the TMJ

AU - Brouxhon, Sabine M.

AU - O'Banion, Michael Kerry

AU - Kyrkanides, Stephanos

N1 - Funding Information: We would like to thank Dr. Ross H. Tallents and Ms. Jen‐nie H. Miller for their assistance in animal care, injection of the viral vectors, animal euthanasia, and tissue processing. We would also like to express our gratitude to Dr. Brandon Harvey, Chief, Molecular Mechanisms of Cellular Stress and Inflammation, and Director of the Transgenic Rat Project, who packaged the AAV vectors at the National Institute for Drug Abuse/National Institute of Health. This study was funded in part by NIH grants AR055035 and DE017765 to S. K., as well as start‐up funding provided to S. K. from the Eastman Dental Foundation through the University of Rochester Eastman Institute for Oral Health. Publisher Copyright: © 2022 The Authors. Clinical and Experimental Dental Research published by John Wiley & Sons Ltd.

PY - 2022/12

Y1 - 2022/12

N2 - Objectives: The goal of this project was to evaluate the use of two adeno-associated viral vector serotypes, adeno-associated viral vectors (AAV)-2 and AAV-6, approved for and used for gene therapy in humans, for the delivery of therapeutic genes to the temporomandibular joint (TMJ) and the attendant sensory nerves. Methods: Young adult wild-type C57BL/6 mice were intra-articularly inoculated with AAV-2 and AAV-6 encoding the reporter gene gfp, the expression of which was assessed in the TMJ as well as along nerves innervating the TMJ. Results: AAV-2 and AAV-6 serotypes were characterized by varying levels of tissue tropism demonstrating different efficacy of infection for articular chondrocytes, meniscal fibroblasts, and trigeminal neurons. Specifically, AAV-2 infected both neurons and articular chondrocytes/meniscal fibroblasts, whereas AAV-6 showed selectivity primarily for neurons. Conclusions: The results of this study are clinically significant in the successful application of gene therapy vectors for TMJ disorders, as this new knowledge will allow for appropriate targeting of specific therapeutic genes to selective tissues (neurons vs. chondrocytes/fibroblasts) as needed by using specific viral vector serotypes.

AB - Objectives: The goal of this project was to evaluate the use of two adeno-associated viral vector serotypes, adeno-associated viral vectors (AAV)-2 and AAV-6, approved for and used for gene therapy in humans, for the delivery of therapeutic genes to the temporomandibular joint (TMJ) and the attendant sensory nerves. Methods: Young adult wild-type C57BL/6 mice were intra-articularly inoculated with AAV-2 and AAV-6 encoding the reporter gene gfp, the expression of which was assessed in the TMJ as well as along nerves innervating the TMJ. Results: AAV-2 and AAV-6 serotypes were characterized by varying levels of tissue tropism demonstrating different efficacy of infection for articular chondrocytes, meniscal fibroblasts, and trigeminal neurons. Specifically, AAV-2 infected both neurons and articular chondrocytes/meniscal fibroblasts, whereas AAV-6 showed selectivity primarily for neurons. Conclusions: The results of this study are clinically significant in the successful application of gene therapy vectors for TMJ disorders, as this new knowledge will allow for appropriate targeting of specific therapeutic genes to selective tissues (neurons vs. chondrocytes/fibroblasts) as needed by using specific viral vector serotypes.

KW - TMJ

KW - gene therapy

KW - trigeminal nerve

KW - vectors

UR - http://www.scopus.com/inward/record.url?scp=85134604477&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85134604477&partnerID=8YFLogxK

U2 - 10.1002/cre2.636

DO - 10.1002/cre2.636

M3 - Article

AN - SCOPUS:85134604477

VL - 8

SP - 1561

EP - 1566

IS - 6

ER -

AAV gene therapy vectors in the TMJ

Abstract

Bibliographical note

Keywords

ASJC Scopus subject areas

Access to Document

Other files and links

Fingerprint

Cite this